Selected research
Industry Growth & Trends
Global Sulfonylurea Hypoglycemic Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Sulfonylurea Hypoglycemic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Sulfonylurea Hypoglycemic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Sulfonylurea Hypoglycemic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Sulfonylurea Hypoglycemic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Sulfonylurea Hypoglycemic Drugs market include United Laboratories, Takeda, Sanofi, Novo Nordisk, Merck, Eli Lilly, Jiangsu Hengrui Pharmaceuticals, Pfizer and Beijing Double-Crane Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Sulfonylurea Hypoglycemic Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Sulfonylurea Hypoglycemic Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Sulfonylurea Hypoglycemic Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Sulfonylurea Hypoglycemic Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Sulfonylurea Hypoglycemic Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Sulfonylurea Hypoglycemic Drugs Market by Company
United Laboratories
Takeda
Sanofi
Novo Nordisk
Merck
Eli Lilly
Jiangsu Hengrui Pharmaceuticals
Pfizer
Beijing Double-Crane Pharmaceutical
Huadong Medicine
GSK
Beijing Beilu Pharmaceutical
AstraZeneca
Boehringer Ingelheim
Sulfonylurea Hypoglycemic Drugs Segment by Type
First Generation Sulfonylureas
Second Generation Sulfonylureas
Third Generation Sulfonylureas
Sulfonylurea Hypoglycemic Drugs Segment by Application
Pharmacy
Hospital
Clinic
Others
Sulfonylurea Hypoglycemic Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sulfonylurea Hypoglycemic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sulfonylurea Hypoglycemic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sulfonylurea Hypoglycemic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Sulfonylurea Hypoglycemic Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- First Generation Sulfonylureas
- Second Generation Sulfonylureas
- Third Generation Sulfonylureas
Applications
- Pharmacy
- Hospital
- Clinic
- Others
Companies covered
- United Laboratories
- Takeda
- Sanofi
- Novo Nordisk
- Merck
- Eli Lilly
- Jiangsu Hengrui Pharmaceuticals
- Pfizer
- Beijing Double-Crane Pharmaceutical
- Huadong Medicine
- GSK
- Beijing Beilu Pharmaceutical
- AstraZeneca
- Boehringer Ingelheim
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Sulfonylurea Hypoglycemic Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Sulfonylurea Hypoglycemic Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Sulfonylurea Hypoglycemic Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Sulfonylurea Hypoglycemic Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Sulfonylurea Hypoglycemic Drugs Market Size (2021-2032)
- 1.5.1 North America Sulfonylurea Hypoglycemic Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Sulfonylurea Hypoglycemic Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Sulfonylurea Hypoglycemic Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Sulfonylurea Hypoglycemic Drugs Market Size Growth Rate (2021-2032)
2 Sulfonylurea Hypoglycemic Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 First Generation Sulfonylureas
- 2.1.2 Second Generation Sulfonylureas
- 2.1.3 Third Generation Sulfonylureas
- 2.2 Global Sulfonylurea Hypoglycemic Drugs Market Size by Type
- 2.2.1 Global Sulfonylurea Hypoglycemic Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Sulfonylurea Hypoglycemic Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Sulfonylurea Hypoglycemic Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Sulfonylurea Hypoglycemic Drugs Market Size by Regions
- 2.3.1 North America Sulfonylurea Hypoglycemic Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Sulfonylurea Hypoglycemic Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Sulfonylurea Hypoglycemic Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Sulfonylurea Hypoglycemic Drugs Market Size Breakdown by Type (2021-2026)
3 Sulfonylurea Hypoglycemic Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Pharmacy
- 3.1.2 Hospital
- 3.1.3 Clinic
- 3.1.4 Others
- 3.2 Global Sulfonylurea Hypoglycemic Drugs Market Size by Application
- 3.2.1 Global Sulfonylurea Hypoglycemic Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Sulfonylurea Hypoglycemic Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Sulfonylurea Hypoglycemic Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Sulfonylurea Hypoglycemic Drugs Market Size by Regions
- 3.3.1 North America Sulfonylurea Hypoglycemic Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Sulfonylurea Hypoglycemic Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Sulfonylurea Hypoglycemic Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Sulfonylurea Hypoglycemic Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Sulfonylurea Hypoglycemic Drugs Industry Trends
- 4.2 Sulfonylurea Hypoglycemic Drugs Industry Drivers
- 4.3 Sulfonylurea Hypoglycemic Drugs Industry Opportunities and Challenges
- 4.4 Sulfonylurea Hypoglycemic Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Sulfonylurea Hypoglycemic Drugs Revenue (2021-2026)
- 5.2 Global Sulfonylurea Hypoglycemic Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Sulfonylurea Hypoglycemic Drugs Key Company Headquarters & Area Served
- 5.4 Global Sulfonylurea Hypoglycemic Drugs Company, Product Type & Application
- 5.5 Global Sulfonylurea Hypoglycemic Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Sulfonylurea Hypoglycemic Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Sulfonylurea Hypoglycemic Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Sulfonylurea Hypoglycemic Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 United Laboratories
- 6.1.1 United Laboratories Company Information
- 6.1.2 United Laboratories Business Overview
- 6.1.3 United Laboratories Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 United Laboratories Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.1.5 United Laboratories Recent Developments
- 6.2 Takeda
- 6.2.1 Takeda Company Information
- 6.2.2 Takeda Business Overview
- 6.2.3 Takeda Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Takeda Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.2.5 Takeda Recent Developments
- 6.3 Sanofi
- 6.3.1 Sanofi Company Information
- 6.3.2 Sanofi Business Overview
- 6.3.3 Sanofi Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sanofi Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.3.5 Sanofi Recent Developments
- 6.4 Novo Nordisk
- 6.4.1 Novo Nordisk Company Information
- 6.4.2 Novo Nordisk Business Overview
- 6.4.3 Novo Nordisk Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Novo Nordisk Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.4.5 Novo Nordisk Recent Developments
- 6.5 Merck
- 6.5.1 Merck Company Information
- 6.5.2 Merck Business Overview
- 6.5.3 Merck Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Merck Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.5.5 Merck Recent Developments
- 6.6 Eli Lilly
- 6.6.1 Eli Lilly Company Information
- 6.6.2 Eli Lilly Business Overview
- 6.6.3 Eli Lilly Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Eli Lilly Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.6.5 Eli Lilly Recent Developments
- 6.7 Jiangsu Hengrui Pharmaceuticals
- 6.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 6.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 6.7.3 Jiangsu Hengrui Pharmaceuticals Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Jiangsu Hengrui Pharmaceuticals Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 6.8 Pfizer
- 6.8.1 Pfizer Company Information
- 6.8.2 Pfizer Business Overview
- 6.8.3 Pfizer Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Pfizer Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.8.5 Pfizer Recent Developments
- 6.9 Beijing Double-Crane Pharmaceutical
- 6.9.1 Beijing Double-Crane Pharmaceutical Company Information
- 6.9.2 Beijing Double-Crane Pharmaceutical Business Overview
- 6.9.3 Beijing Double-Crane Pharmaceutical Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Beijing Double-Crane Pharmaceutical Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.9.5 Beijing Double-Crane Pharmaceutical Recent Developments
- 6.10 Huadong Medicine
- 6.10.1 Huadong Medicine Company Information
- 6.10.2 Huadong Medicine Business Overview
- 6.10.3 Huadong Medicine Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Huadong Medicine Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.10.5 Huadong Medicine Recent Developments
- 6.11 GSK
- 6.11.1 GSK Company Information
- 6.11.2 GSK Business Overview
- 6.11.3 GSK Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 GSK Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.11.5 GSK Recent Developments
- 6.12 Beijing Beilu Pharmaceutical
- 6.12.1 Beijing Beilu Pharmaceutical Company Information
- 6.12.2 Beijing Beilu Pharmaceutical Business Overview
- 6.12.3 Beijing Beilu Pharmaceutical Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Beijing Beilu Pharmaceutical Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.12.5 Beijing Beilu Pharmaceutical Recent Developments
- 6.13 AstraZeneca
- 6.13.1 AstraZeneca Company Information
- 6.13.2 AstraZeneca Business Overview
- 6.13.3 AstraZeneca Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 AstraZeneca Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.13.5 AstraZeneca Recent Developments
- 6.14 Boehringer Ingelheim
- 6.14.1 Boehringer Ingelheim Company Information
- 6.14.2 Boehringer Ingelheim Business Overview
- 6.14.3 Boehringer Ingelheim Sulfonylurea Hypoglycemic Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Boehringer Ingelheim Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 6.14.5 Boehringer Ingelheim Recent Developments
7 North America
- 7.1 North America Sulfonylurea Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Sulfonylurea Hypoglycemic Drugs Market Size by Country (2021-2026)
- 7.3 North America Sulfonylurea Hypoglycemic Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Sulfonylurea Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Sulfonylurea Hypoglycemic Drugs Market Size by Country (2021-2026)
- 8.3 Europe Sulfonylurea Hypoglycemic Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Sulfonylurea Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Sulfonylurea Hypoglycemic Drugs Market Size by Country (2021-2026)
- 10.3 South America Sulfonylurea Hypoglycemic Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Sulfonylurea Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Sulfonylurea Hypoglycemic Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Sulfonylurea Hypoglycemic Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst